Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Background/Aims: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. Methods: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacinbased third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed. Results: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a protonpump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/ gastroduodenal ulcer, 68.8%, p=0.655). Conclusions: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.
Abstract
Background/Aims: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. Methods: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacinbased third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed. Results: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a protonpump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/ gastroduodenal ulcer, 68.8%, p=0.655). Conclusions: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.
참고문헌 (34)
- NIH Consensus Conference, "Helicobacter pylori in peptic ulcer disease:NIH consensus development panel on Helicobacter pylori in peptic ulcer disease", JAMA, 272, pp.65~69 (1994)
- Suerbaum S, "Helicobacter pylori infection", N Engl J Med, 347, pp.1175~1186 (2002)
- Marshall BJ, "Prospective doubleblind trial of duodenal ulcer relapse after eradication of Campylobacter pylori", Lancet, 2, pp.1437~1442 (1988)
- Marshall BJ, "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration", Lancet, 1, pp.1311~1315 (1984)
- Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use: nationwide survey", Helicobacter, 21, pp.266~278 (2016)
- Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
- Mégraud F, "H pylori antibiotic resistance: prevalence, importance, and advances in testing", Gut, 53, pp.1374~1384 (2004)
- Lee JH, "Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults", Antimicrob Agents Chemother, 49, pp.1600~1603 (2005)
- Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
- Gisbert JP, "Third-line rescue therapy with levofloxacin after two H. pylori treatment failures", Am J Gastroenterol, 101, pp.243~247 (2006)
- Gisbert JP, "Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures", Aliment Pharmacol Ther, 24, pp.1469~1474 (2006)
- Tursi A, "Efficacy and tolerability of a third line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection", J Gastrointestin Liver Di, 21, pp.133~138 (2012)
- Gatta L, "A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses", Aliment Pharmacol Ther, 22, pp.45~49 (2005)
- 이지현, "Helicobacter pylori 제균치료에서 Levofloxacin 병합요법의 효과", 대한소화기학회지, 48(1), pp.19~24 (2006), 대한소화기학회
- 정명호, "헬리코박터 파일로리의 3차 구제요법에서 리파부틴과 레보플록사신의 비교", 대한소화기학회지, 59(6), pp.401~406 (2012), 대한소화기학회
- Lee H, "Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea", Dig Liver Dis, 47, pp.114~118 (2015)
- Malfertheiner P, "Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG)", Eur J Gastroenterol Hepatol, 9, pp.1~2 (1997)
- Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report", Aliment Pharmacol Ther, 16, pp.167~180 (2002)
- Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report", Gut, 56, pp.772~781 (2007)
- 공은정, "Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change?", Journal of Korean Medical Science, 29(5), pp.704~713 (2014), 대한의학회
- Megraud F, "Technical annex:tests used to assess Helicobacter pylori infection", Gut, 41(Suppl 2), pp.S10~S18 (1997)
- Sánchez JE, "Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin", dalfopristin and new quinolones, 2000, pp.46, 283~285
- Tanaka M, "Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori", J Antimicrob Chemother, 49, pp.1039~1040 (2002)
- Gisbert JP, "Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients", J Clin Gastroenterol, 47, pp.130~135 (2013)
- Chuah SK, "Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori", Helicobacter, 17, pp.216~223 (2012)
- Sang-Pil Yun, "Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori", Gut and Liver, 6(4), pp.452~456 (2012), 거트앤리버 발행위원회
- Murakami K, "Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan", J Gastroenterol, 48, pp.1128~1135 (2013)
- 김정목, "한국인 환자에서 분리한 Helicobacter pylori 균주의 항생제 내성률", 대한소화기학회지, 47(5), pp.337~349 (2006), 대한소화기학회
- Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
- Di Caro S, "Levofloxacin", amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line, 2012, pp.18, 5669~5678
- Gisbert JP, "Review article: rifabutin in the treatment of refractory Helicobacter pylori infection", Aliment Pharmacol Ther, 35, pp.209~221 (2012)
- Gisbert JP, "‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures", Helicobacter, 8, pp.90~94 (2003)
- Sugimoto M, "High Helicobacter pylori cure rate with sitafloxacin-based triple therapy", Aliment Pharmacol Ther, 42, pp.477~483 (2015)
- Saad RJ, "Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis", Am J Gastroenterol, 101, pp.488~496 (2006)